Literature DB >> 35284297

Phenotypical heterogeneity of mitochondrial encephalopathy with lactic acidosis and stroke-like episodes in a patient with recurrent movement disorder.

Hyug-Gi Kim1, Kyung Mi Lee1.   

Abstract

Entities:  

Year:  2022        PMID： 35284297      PMCID： PMC8899963          DOI： 10.21037/qims-21-802

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN： 2223-4306


× No keyword cloud information.
  5 in total

1.  [Mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (Melas) associated with a Fahr disease and cerebellar calcifications].

Authors:  S Younes-Mhenni; S Thobois; N Streichenberger; P Giraud; B Mousson-de-Camaret; M E Montelescaut; E Broussolle; G Chazot
Journal:  Rev Med Interne       Date:  2002-12       Impact factor: 0.728

2.  Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes with special reference to the mechanism of cerebral manifestations.

Authors:  K Seyama; K Suzuki; Y Mizuno; M Yoshida; M Tanaka; T Ozawa
Journal:  Acta Neurol Scand       Date:  1989-12       Impact factor: 3.209

3.  Neuroradiological features of six kindreds with MELAS tRNA(Leu) A2343G point mutation: implications for pathogenesis.

Authors:  C M Sue; D S Crimmins; Y S Soo; R Pamphlett; C M Presgrave; N Kotsimbos; M J Jean-Francois; E Byrne; J G Morris
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-08       Impact factor: 10.154

4.  Oculocraniosomatic neuromuscular disease with hypoparathyroidism.

Authors:  M Toppet; N Telerman-Toppet; H B Szliwowski; M Vainsel; C Coers
Journal:  Am J Dis Child       Date:  1977-04

5.  Correction of the consequences of mitochondrial 3243A>G mutation in the MT-TL1 gene causing the MELAS syndrome by tRNA import into mitochondria.

Authors:  Olga Z Karicheva; Olga A Kolesnikova; Tom Schirtz; Mikhail Y Vysokikh; Anne-Marie Mager-Heckel; Anne Lombès; Abdeldjalil Boucheham; Igor A Krasheninnikov; Robert P Martin; Nina Entelis; Ivan Tarassov
Journal:  Nucleic Acids Res       Date:  2011-06-30       Impact factor: 16.971
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.